Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia

Yishai Ofran; Shimrit Ringelstein-Harlev; Ilana Slouzkey; Tsila Zuckerman; Dana Yehudai-Ofir; Israel Henig; Ofrat Beyar-Katz; Michal Hayun; Avraham Frisch

doi:10.1038/s41375-019-0548-z

Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia

Yishai Ofran^*, Shimrit Ringelstein-Harlev, Ilana Slouzkey, Tsila Zuckerman, Dana Yehudai-Ofir, Israel Henig, Ofrat Beyar-Katz, Michal Hayun, Avraham Frisch

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

60 Scopus citations

Original language	English
Pages (from-to)	293-295
Number of pages	3
Journal	Leukemia
Volume	34
Issue number	1
DOIs	https://doi.org/10.1038/s41375-019-0548-z
State	Published - 1 Jan 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41375-019-0548-z

Cite this

@article{baadd1e31b77460ba5c769bba7c09805,

title = "Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia",

author = "Yishai Ofran and Shimrit Ringelstein-Harlev and Ilana Slouzkey and Tsila Zuckerman and Dana Yehudai-Ofir and Israel Henig and Ofrat Beyar-Katz and Michal Hayun and Avraham Frisch",

year = "2020",

month = jan,

day = "1",

doi = "10.1038/s41375-019-0548-z",

language = "אנגלית",

volume = "34",

pages = "293--295",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia

AU - Ofran, Yishai

AU - Ringelstein-Harlev, Shimrit

AU - Slouzkey, Ilana

AU - Zuckerman, Tsila

AU - Yehudai-Ofir, Dana

AU - Henig, Israel

AU - Beyar-Katz, Ofrat

AU - Hayun, Michal

AU - Frisch, Avraham

PY - 2020/1/1

Y1 - 2020/1/1

UR - http://www.scopus.com/inward/record.url?scp=85070968392&partnerID=8YFLogxK

U2 - 10.1038/s41375-019-0548-z

DO - 10.1038/s41375-019-0548-z

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 31435023

AN - SCOPUS:85070968392

SN - 0887-6924

VL - 34

SP - 293

EP - 295

JO - Leukemia

JF - Leukemia

IS - 1

ER -

Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia

UN SDGs

Access to Document

Other files and links

Cite this